EGFR and non-small cell lung carcinoma: In the current study, we found that the combination therapy of EGFR–TKI, denosumab, and an anti‐VEGF agent significantly improved OS compared to EGFR–TKI monotherapy in patients with EGFR‐mutated NSCLC.